Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang

Table 4 Serum metabolite profiles of MG patients before and after QJF treatment

Metabolite	Formula	± ppm^a	Peak area (Mean ± SD^b)		% Change^c	P value^d
Metabolite	Formula	± ppm^a	Before therapy	After therapy	% Change^c	P value^d
γ-aminobutyric acid	C₄H₉NO₂	−71.7	10.2 ± 0.52	15.80 ± 0.81	54.9	0.000
Coenzyme Q4	C₂₉H₄₂O₄	43.1	12.28 ± 3.41	7.89 ± 0.89	−35.7	0.000
Taurallocholic acid	C₂₆H₄₅NO₇S	−75.8	0.03 ± 0.17	6.72 ± 5.32	19016.7	0.000
Dipalmitoylphosphatidic acid	C₃₅H₆₉O₈P	92.9	0.19 ± 0.38	6.65 ± 2.35	3397.8	0.000
Phytosphingosine	C₁₈H₃₉NO₃	−2.3	1.73 ± 1.53	19.11 ± 7.29	1004.8	0.000
5b-Cyprinolsulfate	C₂₇H₄₈O₈S	−50.2	0.38 ± 0.61	2.63 ± 2.01	591.9	0.000
Thromboxane B2	C₂₀H₃₄O₆	40	1.13 ± 1.45	2.92 ± 1.91	158.3	0.000
Biliverdin IX	C₃₃H₃₄N₄O₆	3.6	22.71 ± 5.78	6.36 ± 3.54	−71.9	0.000

^aMass differences between the calculated and measured metabolite masses.
^bMean peak areas of metabolites in patients before and after QJF treatment. SD denotes standard deviation.
^cChanges are calculated as the difference in the median concentrations before and after QJF treatment.
^dP values were calculated by Student’s t-test.

ISSN: 1749-8546